EBMT 2022 | Emerging treatment options for HSCT-TMA
Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, comments on agents under investigation for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). Before the introduction of complement inhibitors, there were no effective treatment options for HSCT-TMA. Eculizumab is now used in many centers and is showing promising results in both pediatric and adult patients. Dr Gavriilaki also mentions narsoplimab, which is currently under investigation along with many other agents targeting the complement system. Defibrotide is another potential treatment option for HSCT-TMA. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Dr Gavriilaki has served as a consultant and/or received honoraria from Alexion Pharmaceuticals, Omeros Corporation, and Sanofi. Dr Gavriilaki has received research support from Jazz Pharmaceuticals.
